{"title":"Genmab与Janssen Biotech达成协议，进一步验证其DuoBody™技术","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I7.1784","DOIUrl":null,"url":null,"abstract":"Genmab has made further progress with its DuoBody™ technology platform by agreeing to collaborate with Johnson & Johnson’s Janssen Biotech to create and develop bispecific antibodies against multiple disease targets. Janssen will fund all research and Genmab will receive US$3.5 M upfront plus potential milestone and licence payments of up to US$175 M for each product successfully developed from the collaboration as well as royalties on sales of any commercialised products. Amgen’s US$1.16 B acquisition of Micromet in March 2012 fuelled industry interest in bispecific antibody technologies.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"60 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Genmab Further Validates its DuoBody™ Technology with Janssen Biotech Agreement\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I7.1784\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Genmab has made further progress with its DuoBody™ technology platform by agreeing to collaborate with Johnson & Johnson’s Janssen Biotech to create and develop bispecific antibodies against multiple disease targets. Janssen will fund all research and Genmab will receive US$3.5 M upfront plus potential milestone and licence payments of up to US$175 M for each product successfully developed from the collaboration as well as royalties on sales of any commercialised products. Amgen’s US$1.16 B acquisition of Micromet in March 2012 fuelled industry interest in bispecific antibody technologies.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"60 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I7.1784\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I7.1784","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Genmab Further Validates its DuoBody™ Technology with Janssen Biotech Agreement
Genmab has made further progress with its DuoBody™ technology platform by agreeing to collaborate with Johnson & Johnson’s Janssen Biotech to create and develop bispecific antibodies against multiple disease targets. Janssen will fund all research and Genmab will receive US$3.5 M upfront plus potential milestone and licence payments of up to US$175 M for each product successfully developed from the collaboration as well as royalties on sales of any commercialised products. Amgen’s US$1.16 B acquisition of Micromet in March 2012 fuelled industry interest in bispecific antibody technologies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
